NewAmsterdam Pharma Company N.V. - Warrant (NAMSW)

On our desk, we are monitoring the $28.1M aggregate capital invested by 9 institutional funds into NAMSW during Q2 2026. Despite zero new funds opening positions, the existing holders like Frazier Life Sciences and RA Capital are maintaining stable stakes. The warrant valuation is entirely tied to the binary long-term success of obicetrapib, making near-term revenue fluctuations secondary to upcoming clinical catalysts.

Looking at the fundamental financials from the Q2 2026 report, the company's sales dropped precipitously to $3.7 million while net losses widened to $64.14 million. However, with $678.3 million in cash, cash equivalents, and marketable securities as of June 30, 2026, liquidity burn is well-covered for the intermediate term, providing runway through the key data readouts expected in late 2026 and early 2027.

From a clinical protocol standpoint, the recent positive CHMP opinion recommending marketing authorization for obicetrapib and obicetrapib/ezetimibe is a major de-risking event. We are closely tracking the upcoming milestones, specifically the RUBENS Phase 3 topline data expected by year-end 2026 and the PREVAIL interim analysis scheduled for Q4 2026 with results in Q1 2027.

Watching the market sentiment on NAMS and NAMSW, retail and institutional forums are sharply divided. While Simply Wall St highlights the plunging sales and doubling H1 net losses up to $112.58 million, long-term bulls remain hyper-focused on the cardiovascular disease market opportunity for non-statin therapies targeting elevated LDL-C.

As a bio-analyst evaluating the pipeline, obicetrapib's regulatory progress in Europe sets a strong precedent. The key question for our clinical modeling is how the European marketing authorization translates into commercial traction, while we simultaneously await the critical US and global trial readouts from PREVAIL and RUBENS.